Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997)  by Jones, Ronald N. et al.
ORIGINAL ARTICLE 
Antimicrobial activity evaluations of gatifloxacin, a new 
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and the SENTRY Antimicrobial Surveillance Program Participants (The Americas) 
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Objective: To investigate the in vitro potency and spectrum of activity of gatifloxacin and five comparator fluoro- 
quinolones tested against over 23 000 clinical isolates from diverse geographic and clinical sources in  the Americas. 
Methods: Gram-negative, Gram-positive and fastidious bacterial isolates were tested against gatifloxacin, ciprofloxacin, 
levofloxacin, ofloxacin, sparfloxacin and trovafloxacin using broth microdilution methods recommended by the National 
Committee for Clinical Laboratory Standards (NCCLS). 
Results: Gatifloxacin demonstrated a potency and spectrum very similar to those of other new fluoroquinolones such 
as levofloxacin, sparfloxacin, and trovafloxacin. Gatifloxacin was particularly active against the Enterobacteriaceae 
(94.8% susceptible at S2 mg/L), Acinetobacter spp. (77.2%), Stenotrophomonas rnaltophilia (75.1%), Streptococcus 
pneurnoniae (99.8%), other Streptococcus spp. (198.9%), and various Staphytococcus spp. (79.2-100.0%). Trovafloxacin 
was the most similar comparison drug overall. 
Conclusions: These results indicate a potential therapeutic role for gatifloxacin that would widen the potency or 
spectrum of fluoroquinolones, particularly against Gram-positive species, when considering its favorable bioavailability. 
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INTRODUCTION 
Gatifloxacin (AM-1155 or CG5501) is a new 8- 
methoxy fluoroquinolone with demonstrated anti- 
bacterial activity against a broad range of Gram-positive 
or -negative organisms, anaerobes and many fastidious 
species [1-6]. As a group, the fluoroquinolones inhibit 
various topoisomerases [7], which prevents bacterial 
replication at the DNA level. Ciprofloxacin, the first 
used broad-spectrum fluoroquinolone, remains the 
leader among the avdable agents as measured by usage, 
but the newer fluoroquinolones with expanded Gram- 
positive potencies may prove to be valuable in the 
treatment of some currently refractory pathogens 
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[8-111. The limitations of ciprofloxacin and ofloxacin 
(dosing frequency and spectrum) have led to the 
development of gatifloxacin, trovafloxacin, sitafloxacin 
(DU-6859), levofloxacin, and sparfloxacin, each of 
which can be administered once daily to treat a wider 
variety of infections [l-6,9-111. These infections 
would include those caused by penicillin-resistant 
Streptococcus spp., multiresistant enterococci, oxacan- 
resistant Staphylococcus spp., and some anaerobes [8]. 
The continuing problem of microbial resistance to 
marketed antimicrobial agents has prompted many 
within government, industry and the academic 
community to propose the initiation of comprehensive 
programs aimed at curbing the emerging resistances 
[12]. To address this problem, the SENTRY Anti- 
microbial Surveillance Program was initiated in early 
1997 [13]. During the first year over 35 000 strains 
were isolated fiom 72 medical centers worldwide, of 
which 23 000 isolates from Canada, the USA, and Latin 
America were processed at the University of Iowa 
College of Medicine (Iowa City, Iowa, USA). The 
scope of the study encompassed ciprofloxacin, gati- 
floxacin, levofloxacin, ofloxacin, sparfloxacin and trova- 
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floxacin, tested against isolates categorized by site of 
infection. The results of these in vitro trials using 
reference dilution methods [14,15] are reported here. 
MATERIALS AND METHODS 
Gatifloxacin was kindly provided by BristoI-Myers 
Squibb (Princeton, NJ, USA). All other antimicrobials 
were supplied by their respective manufacturers. Gati- 
floxacin and five other fluoroquinolones were evaluated 
in various study phases using a collection of over 23 000 
clinical isolates. The isolates were taken fiom the 1997 
SENTRY Program, which included strains from 48 
medical centers in Canada, the USA and Latin America 
(six countries) [13]. This surveillance program moni- 
tors consecutive isolates in a prevalence study design 
using local clinical isolates from: the bloodstream (20 
isolates/monthx 12 months per center); community- 
acquired respiratory tract infections caused by Strepto- 
coccus pneumoniae, Haemophilus influenzae, and Moraxella 
catarrhalis; pneumonia in hospitalized patients; skin and 
soft tissue infections; and urinary tract infections. 
Approximately equal numbers of strains were con- 
tributed by each participant, and differences in the 
endemic resistance patterns of fluoroquinolones have 
been observed, with rates greater in Latin America> 
USAXanada (data on file). The six compounds were 
tested using broth microdilution methods recom- 
mended by the National Committee for Clinical 
Laboratory Standards (NCCLS) [14,15]. The fluoro- 
quinolones were tested over the following log2 
dilution schedules: gatifloxacin at 50.03-4 mg/L, 
ciprofloxacin at 50.06-2 mg/L, levofloxacin at 
50.5-4 mg/L, ofloxacin at 50.03-4 mg/L, spar- 
floxacin at 50.25-2 mg/L and trovafloxacin at 
10.03-4 mg/L. 
All non-fastidious organisms were inoculated 
into cation-adjusted Mueller-Hinton broth and then 
incubated for 16-20 h at 35OC in ambient air. The 
streptococci were inoculated into cation-adjusted 
Mueller-Hinton broth supplemented with 3-5% lysed 
horse blood, and then incubated for 24 h at 35°C in 
ambient air. H. influenzae and H. parainfluenzae were 
tested in Haemophilus Test Medium (HTM) incubated 
for 24 h at 35°C in ambient air. Two types of panels 
were utilized for this investigation. Frozen panels, 
stored at -7O"C, were manufactured by PML Micro- 
biologics (Wilsonville, OR, USA). Dade Microscan 
(Sacramento, CA, USA) dry-form panels were also 
utilized in determining organism MICs. The MIC 
panels were interpreted manually and results validated 
using the appropriate American Type Culture Collec- 
tion (ATCC) quality control strains in accordance with 
NCCLS documents [15]. These strains included Escher- 
ichia coli ATCC 25922, Staphylococcus aureus ATCC 
29213, Enterococcus faecalis ATCC 29212, Pseudomonas 
aeruginosa ATCC 27853, H .  influenzae ATCC 49247, 
and Streptococcus pneumoniae ATCC 49619. 
Gatifloxacin activity against Enterobacteriaceae 
Table 1 lists the comparative activities of six fluoro- 
quinolones tested against over 5000 strains of Entero- 
bacteriaceae. Many of these strains had emerging 
problematic resistances to other antimicrobial agents. 
Among the Citrobacter spp. and Enterobacter spp., only 
74.5-79.6% of strains were susceptible to 'third- 
generation' cephalosporins (data not shown). Resistant 
strains were phenotypically consistent with producing 
Bush-Jacoby-Mederios group 1 stably derepressed p- 
lactamases. Similarly, some Escherichia coli (3.0%) and 
Klebsiella spp. (5.9%) strains had elevated ceftazidime 
MICs ( 2 2  mg/L), representing the production of 
extended-spectrum p-lactamases (ESBLs) (see foot- 
notes to Table 1). 
Generally, ciprofloxacin was most active (see 
MIC5o values). Gatifloxacin and trovafloxacin had a 
median MIC50 of 0.06 mg/L and a median MICW of 
1 rng/L. At breakpoint concentrations published in 
NCCLS documents or justified by pharmacodynamic 
criteria, the rank order of spectrum was as follows: 
levofloxacin (96.1%) > gatifloxacin (94.8% at 5 2  
mg/L) > ofloxacin (94.5%) > ciprofloxacin (94.4%) > 
trovafloxacin (91.5% at 1 1 mg/L) > sparfloxacin 
(91.1%). The most resistant isolates were the Serratia 
spp. (225 strains) that had MIC90 results of 1-4 mg/L 
for trovafloxacin and sparfloxacin, and only inhibited 
78.2% and 80.9%, respectively, of strains at 1 mg/L. All 
other tested fluoroquinolones inhibited 89.8-94.2% of 
the Serratia spp. isolates at recognized susceptible 
concentrations. Also, Morganella morganii (59 strains) 
was less susceptible to the newer fluoroquinolones such 
as trovafloxacin (MIC9,,, > 4 mg/L) and sparfloxacin 
> 2 mg/L) when compared to older com- 
pounds in the class (ciprofloxacin MICw, 2 mg/L). 
Gatifloxacin activity against non-fermentative 
Gram-negative bacilli 
In Table 2, three species groups of non-fermentative 
Gram-negative bacilli are listed with MIC results for 
the six fluoroquinolones. Against the Acinetobacter spp. 
strains, trovafloxacin was most active (MICw, 0.06 
mg/L) among the agents with on-scale results, but, 
most importantly, the overall spectra of the six 
compounds did not significantly differ (72.8-78.1% 
susceptible). The Pseudomonas aeruginosa isolates varied 
widely in their susceptibility to the fluoroquinolones, 
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Table 1 Antimicrobid activity of gatifloxacin and five comparison fluoroquinolones tested against 5034 Enterobacteriaceae 
strains (SENTRY Antimicrobial Surveillance Program, 1997) 
~~ 
MIC (mg/L) 
% inhbited 
Organum (no. tested) Antimicrobial agent 50% 90% Range (breakpomt) 
Enterobacter spp. (647)b 
Escherichia coli (2527)' 
Mebsiella spp. (1089)d 
Motgunella morganii (59) 
Pantoea qglomerans (38) 
I? mirabilis (242) 
Salmonella spp. (45) 
Serrafia spp. (225) 
Citrobmfer spp. (162)a Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spadoxacin 
Trovafloxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trovailoxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trovafloxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trodoxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trodoxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trodoxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Spdoxacin 
Trodoxacin 
Gatdoxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Trovafloxacin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Ofloxacin 
Sparfloxacin 
Trovafloxacin 
Spdoxacin 
0.06 
0.03 
10.5 
0.12 
10.25 
0.06 
0.06 
0.03 
10.5 
0.12 
50.25 
0.06 
10.03 
10.016 
50.5 
0.06 
10.25 
50.03 
0.12 
0.03 
10.5 
0.12 
10.25 
0.12 
0.12 
10.016 
10.5 
0.06 
50.25 
0.25 
0.06 
0.03 
10.5 
0.12 
50.25 
0.06 
0.25 
0.03 
50.5 
0.12 
10.25 
0.25 
0.06 
10.016 
10.5 
0.12 
10.25 
50.03 
0.5 
0.12 
10.5 
0.25 
0.5 
0.5 
1 
0.5 
1 
2 
2 
2 
1 
0.5 
10.5 
1 
1 
1 
0.06 
0.06 
10.5 
0.12 
50.25 
0.12 
0.5 
0.25 
10.5 
1 
0.5 
1 
4 
2 
2 
4 
>2 
>4 
0.12 
0.25 
50.5 
0.25 
0.5 
0.5 
1 
0.25 
10.5 
1 
2 
1 
0.12 
0.06 
50.5 
0.12 
10.25 
0.12 
4 
1 
2 
2 
2 
4 
50.03 to >4 
50.016 to >2 
10.5 to >4 
10.03 to 24 
10.25 to >2 
10.03 to >4 
10.03 to >4 
10.016 to >2 
10.5 to >4 
10.03 to >4 
10.25 to 22 
10.03 to >4 
10.03 to >4 
50.016 to >2 
10.5 to >4 
10.03 to >4 
50.25 to >2 
10.03 to >4 
10.03 to >4 
50.016 to >2 
10.5 to >4 
10.03 to >4 
10.25 to >2 
10.03 to >4 
10.03 to >4 
10.016 to >2 
10.5 to >4 
10.03 to >4 
10.25 to >2 
0.03 to >4 
10.03-4 
10.16-2 
10.5-4 
0.06-4 
10.25-2 
50.03-4 
0.06 to >4 
10.016 to >2 
10.5 to >4 
10.03 to >4 
10.25 to >2 
10.03 to >4 
10.06-0.25 
50.016 to >2 
10.5 
0.06-1 
10.25 to >2 
10.03-4.5 
10.03 to >4 
10.016 to >2 
50.5 to >4 
0.06 to >4 
10.25 to >2 
10.03 to >4 
92.6 (52) 
92.0 (11) 
93.8 (12) 
92.6 (52) 
86.4 (11) 
87.0 (11) 
95.2 (12) 
93.0 (51) 
93.0 (12) 
91.3 (11) 
91.5 (11) 
94.9 (12) 
97.9 (12) 
97.5 (51) 
97.9 (12) 
97.7 (11) 
97.4 (51) 
97.6 (12) 
96.9 (12) 
95.6 (11) 
97.1 (12) 
95.0 (11) 
93.8 (51) 
89.8 (12) 
89.8 (11) 
91.5 (12) 
89.8 (12) 
88.1 (51) 
88.1 (11) 
97.2 (12) 
97.2 (11) 
94.9 (12) 
97.4 (12) 
97.4 (12) 
94.7 (11) 
97.4 (11) 
94.2 (12) 
96.3 (11) 
95.0 (12) 
88.4 (11) 
90.1 (11) 
97.9 (12) 
100.0 (12) 
97.7 (11) 
100.0 (12) 
100.0 (12) 
100.0 (11) 
97.8 (11) 
89.8 (12) 
90.7 (11) 
94.2 (12) 
90.2 (12) 
80.9 (11) 
78.2 (11) 
Stably derepressed Bush group 1 isolates (ceftazidime MIC 2 16 mg/L)=20.4% of tested strains. 
bStably derepressed Bush group 1 isolates (ceftazidime MIC 216 mg/L)=25.5% of tested strains. 
'ESBL-phenotypes (ceftazidime MIC at 2 2  mg/L)=3.0% of tested strains. 
dESBL-phenotypes (ceftizidime MIC at 1 2  mg/L)=5.9% of tested strains. 
ESBL, extended-spectrum p-lactamase. 
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Table 2 Antimicrobial activity of gatifloxacin and five comparator quinolones tested against the three most prevalent non- 
fermentative Gram-negative bacilli (1536 strains) isolated in the SENTRY Antimicrobial Surveillance Program, 1997 
Pseudomonas aenrginosa (1 135)" 
MIC (mg/L) 
% inhibited 
Organism (no. tested) Antimicrobial agent 50% 90% Range (breakpoint) 
Acinetobncfer spp. (224) Gatifloxacin 0.12 >4 10.03-4 77.2 (52) 
Ciprofloxacin 0.25 >2 50.016 to >2 72.8 (51) 
Levofloxacin 50.5 >4 50.5 to >4 76.3 (52) 
Sparfloxacin 10.25 >2 50.25 to >2 77.2 (11) 
Trovdoxacin 0.06 >4 10.03 to >4 78.1 (11) 
Gatifloxacin 1 >4 50.03 to >4 68.5 (52) 
Ofloxacin 0.25 >4 50.03 to >4 75.4 (12) 
Ciprofloxacin 0.25 22  50.016 to >2 79.8 ( 5 1 )  
Levofloxacin 10 .5  24 50.5 to 2 4  74.4 (52) 
Ofloxacin 1 >4 50.03 to >4 66.6 ( 5 2 )  
Sparfloxacin 1 >2 50.25 to >2 60.2 (5 1) 
Trovafloxacin 1 >4 50.03 to 24  65.9 (51) 
Sfenotrophomonas maltophilia (177) Gatifloxacin 1 4 50.03 to >4 75.1 (52) 
Ciprofloxacin 2 >2 0.03 to >2 20.9 (51) 
Levofloxacin 1 4 50.5 to >4 78.0 (52) 
Ofloxacin 2 >4 50.03 to >4 56.5 (52) 
Sparfloxacin 0.5 2 50.25 to >2 76.8 (51) 
Trovafloxacin 1 4 50.03 to >4 70.6 (51) 
"Greater than 90% coverage only noted for amikacin (93.8%). meropenem (92.2%). tobramycin (91.0%), and piperacdhdtazobactam (90.7%). 
with ciprofloxacin remaining most active (79.8%) and 
sparfloxacin having the narrowest spectrum of activity 
(60.2%). Among the other tested agents, levofloxacin 
was approximately two-fold more potent than gati- 
floxacin, trovafloxacin, and ofloxacin. 
Strains of Stenotrophomonas maltophilia were only 
marginally susceptible to some of the tested fluoro- 
quinolones. Ciprofloxacin and ofloxacin demonstrated 
the least activity (MICso 2 mg/L) and the poorest 
susceptibility rates of 20.9% and 56.5%, respectively. 
Gatifloxacin (75.1%), spadoxacin (76.8%) and levo- 
floxacin (78.0%) showed potential therapeutic promise. 
To place the above results in perspective, other 
tested antimicrobial agents exhibiting the greatest 
activity against the most prevalent species in this group, 
Pseudomonas aeruginosa, were amikacin (93.8% suscept- 
ible), meropenem (92.2%), tobramycin (91.0%), and 
piperacillin/tazobactam (90.7%) (data not shown). 
Gatifloxacin activity against fastidious organisms 
Table 3 summarizes the in vitro results for nearly 4000 
strains of H. infuenzae, H. parainfuenzae, Moraxella 
catarrhalis, and Streptococcus pneumoniae. Among the H. 
infuenzae, strains, 36.2% were ampicillin/amoxyciUin 
resistant by virtue of P-lactamase production. However, 
gatifloxacin and the other tested fluoroquinolones were 
all very active (MIC90s 10.5 mg/L). The highest 
recorded H. infuenzae MIC for a fluoroquinolone was 
1 mg/L for levofloxacin, and all other compounds had 
MICs 50.25 mg/L. Moraxella catarrhalis was also very 
susceptible to the fluoroquinolones, regardless that 90% 
of strains produced a detectable P-lactamase (data not 
shown). Pneumococci were often resistant to penicillin 
(60.3% susceptible at 50.06 mg/L), and many of these 
strains were also resistant to macrolides (erythromycin 
susceptibility at 86.7%). Gatifloxacin, sparfloxacin and 
trovafloxacin (MIC90, 0.5 mg/L) were equally active 
and generally four-fold more potent than ciprofloxacin 
or levofloxacin versus Streptococcus pneumoniae. At 
published or proposed interpretive breakpoint concen- 
trations [15-171, gatifloxacin ( 5 2  mg/L), levofloxacin 
( 5 2  mg/L), sparfloxacin (10.5 mg/L) and trova- 
floxacin ( 5 1  mg/L) were very active (98.4-99.896 
susceptible). High-level resistance to these agents has 
been secondary to multiple mutations in topoisomerase 
genes (gyrA, parC) [7] and has usually produced 
complete cross-resistance among the fluoroquinolones 
tested here. 
Gatifloxacin activity against Gram-positive organisms 
The MIC testing results for non-pneumococcal strep- 
tococci, Staphylococcus spp. and enterococci are shown 
in Table 4. Only four fluoroquinolones were routinely 
assessed against these species in the SENTRY Program, 
and the rank order of spectrum and potency for 
the P-hemolpc and viridans group streptococci was: 
gatifloxacin = spadoxacin = trovafloxacin (MIC90, 
0.5 mg/L; 98.3-99.7% susceptible) > ciprofloxacin 
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Table 3 Antimicrobial activity of gatifloxacin compared to five or s ix  other orally administered antimicrobial agents tested 
against 3738 strains of Huemophilus species, Moraxellu cuturrhulis and Streptococrus pneumoniue (SENTRY Antimicrobial 
Surveillance Program, 1997) 
MIC (mg/L) 
% inhibited" 
Organism (no. tested) Antimicrobial agent 50% 90% Range (breakpoint) 
H. inyuenzae (1403) 
H. parainzuenzae (13) 
Mormella catanltalis (605) 
Streptoroms pneumoniae (1717) 
Amoxycillin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacin 
Amoxycikn 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Sparfloxacin 
Trovafloxacin 
Amoxycihn 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Sparfloxacin 
Trovafloxacin 
PeniciUln 
Erythromycin 
Gatifloxacin 
Ciprofloxacin 
Levofloxacin 
Sparfloxacin 
Trovafloxacin 
1 
10.03 
50.016 
50.5 
50.12 
50.03 
0.5 
10.03 
50.015 
10.5 
50.12 
0.06 
4 
50.03 
0.03 
50.5 
10.12 
10.03 
0.06 
50.25 
0.5 
1 
1 
0.25 
0.25 
>8 
10.03 
10.016 
10.5 
10.12 
10.03 
2 8  
0.12 
0.03 
50.5 
10.12 
0.25 
8 
10.03 
0.03 
10.5 
50.12 
50.03 
2 
1 
0.5 
2 
2 
0.5 
0.5 
50.06 to >8 
50.0?-0.25 
50.01&-0.25 
50.5-1 
10.12-0.25 
50.03-0.25 
0.25 to >8 
10.034.5 
10.15-1 
10.5-2 
50.12-1 
50.03-1 
10.06 to >8 
10.03-1 
10.016-1 
50.5-2 
5 0 . 1 2 4 5  
50.03-0.5 
50.008 to >I6 
10.25 to >32 
0.06 to >4 
50.016 to >2 
50.5 to >4 
50.12 to >I 
10.03->4 
63.8 (12) 
100.0 (12) 
100.0 (11) 
100.0 (12) 
100.0 (51) 
100.0 (11) 
100.0 (52) 
100.0 (11) 
100.0 (12) 
100.0 (51) 
100.0 (51) 
100.0 (12) 
100.0 (51) 
100.0 (52) 
100.0 (<I) 
100.0 (11) 
84.6 (12) 
8.9 (10.12) 
60.3 (50.06) 
86.7 (S0.25) 
99.8 (11) 
99.2 (12) 
98.4 (50.5) 
99.8 (11) 
- WYb 
"Concentration in parentheses indicates criteria applied. MIC breakpoint for susceptibihty was that of the NCCLS [I51 when available. 
bNA, not applicable. Penicillin results used to predict the clinical utility of many oral cephalosporins. No criteria have been published for 
ciprofloxacin. 
(MIC90, 1 to >2 mg/L). Gatifloxacin (MIC90, 4 mg/L) 
was routinely more active than comparison drugs 
against the coagulase-negative staphylococci, while 
trovafloxacin (MIc90,2 mg/L) was most active against 
the Staphylococcus aureus strains. Approximately two- 
thirds of Enterococcus faecalis strains were susceptible to 
gatifloxacin, sparfloxacin and trovafloxacin, but only 
48.9% were inhibited by 51 mg/L of ciprofloxacin. 
Enterococcus faecium strains (often multiresistant, includ- 
ing glycopeptide resistances) were less susceptible 
(8.3-17.5%) to all tested fluoroquinolones. 
CONCLUSIONS 
Using a geographically diverse sample of clinical isolates 
collected in 1997 f?om the Americas, gatifloxacin 
activity and spectrum were compared to those of other 
broad-spectrum fluoroquinolones. As noted in earlier 
investigations 11-61, gatifloxacin demonstrated a potency 
and spectrum very similar to those of levofloxacin [9], 
sparfloxacin [16], and trovafloxacin [18]. Gatifloxacin 
was particularly active against the Enterobacteriaceae 
(94.8% susceptible at 5 2  mg/L), Acinetobacter spp. 
(77.2%), Stenotrophomonas maltophilia (75.1%), Strepto- 
coccus pneumoniae (99.8%). other Streptococcus spp. 
(298.9%), and various Staphylococcus spp. (79.2- 
100.0%). The most prevalent enterococcus, Ertterococcus 
faeculis, was also susceptible to gatifloxacin (MIC50, 
0.5 mg/L). Trovafloxacin was the most sirmlar com- 
parison drug overall [17,18]. These results indicate a 
potential therapeutic role for gatifloxacin that would 
widen the spectrum or potency of fluoroquinolones 
against several Gram-positive species, especially associ- 
ated with its favorable bioavailability [l l] ,  which 
includes a C ,  of 3.35 mg/L, elimination half-life of 
7-8 h and a 24-h AUC of 32.4 mg.h/L following a 
single 400-mg oral dose. We anxiously await the results 
of the clinical trials and the assessment of safety. 
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